Additionally, TP53 mutations may lead to the acquisition of gain-of-function (GOF) activities, responsible for more aggressive tumor phenotypes with increased invasive and metastatic potential, high chemoresistance, and poor prognosis [3–5]. This evidence concerns the gene TP53 and neoplasm.